Grove Bank & Trust reduced its holdings in Abbott Laboratories by nearly 20% in Q4, selling 6,678 shares worth about $3.36 million. Meanwhile, Abbott is set to complete its acquisition of Exact Sciences on March 23, 2026, expanding its cancer diagnostics business. The company reported Q4 earnings in line with expectations and announced a quarterly dividend of $0.63 per share. Despite some analyst price target cuts, Abbott maintains a moderate buy rating with growth prospects tied to diagnostics and aging population trends.
Abbott posted a 13% increase in reported sales and 4.8% comparable sales growth for Q2 2026, with GAAP diluted EPS at $0.53 and adjusted EPS at $1.31. The company reaffirmed its full-year 2026 sales growth guidance of 6.5% to 7.5% and raised its adju...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
